Biotech executives reveal concerns over Chinese biotech, the profitability of AI, and the durability of Trump's drug price moves.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | BIO 2026: AI, federal policy impacts, and general vibes | 0 | 5 | 26-06-2026 |
| 2 | STAT+: Embryo editing advances reignite ethical debates | 0 | 5 | 26-06-2026 |
| 3 | Nvidia's China-bound H20 AI chips face Beijing scrutiny over ‘tracking' and security concerns | 0 | 7 | 31-07-2025 |
| 4 | Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days | 0 | 5 | 31-07-2025 |
| 5 | STAT+: Proposed CDC science office could tighten political control at agency | -3 | 6 | 25-06-2026 |
| 6 | Supreme Court rules in weedkiller cancer case | 0 | 5 | 26-06-2026 |
| 7 | Pandemic darlings Moderna, BioNTech are now on two different paths | 0 | 7 | 31-07-2025 |
| 8 | Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum And Strong Product-Level Performance Of GRAFAPEX (Treosulfan) For Injection | 5 | 5 | 25-06-2026 |
| 9 | STAT+: Next-gen CRISPR tools improve editing accuracy in embryos, but also stoke ethical concerns | 0 | 7 | 25-06-2026 |
| 10 | Деловой дайджест: 26–31 мая 2026 года | 0 | 7 | 01-01-1970 |